China proposes new limits on foreign biotech acquisitions to protect domestic drug development

China is drafting new rules that would restrict foreign companies from acquiring Chinese biotech assets deemed critical to the nation's drug development sector.

The proposal aims to keep control over emerging biopharma technologies within China, reflecting a broader strategy to safeguard its growing pharmaceutical industry.

The move could affect foreign investors and multinational biotech firms seeking to expand in China, potentially slowing cross‑border deals in the sector.